title: Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene.
abstract: Various HIV-1 env genetic and biochemical features impact the elicitation of cross-reactive neutralizing antibodies in natural infections. Thus, we aimed to investigate cross-neutralizing antibodies in individuals infected with HIV-1 env subtypes B, F1, C or the B/Bbr variant as well as env characteristics. Therefore, plasma samples from Brazilian chronically HIV-1 infected individuals were submitted to the TZM-bl neutralization assay. We also analyzed putative N-glycosylation sites (PNGLs) and the size of gp120 variable domains in the context of HIV-1 subtypes prevalent in Brazil. We observed a greater breadth and potency of the anti-Env neutralizing response in individuals infected with the F1 or B HIV-1 subtypes compared with the C subtype and the variant B/Bbr. We observed greater V1 B/Bbr and smaller V4 F1 than those of other subtypes (p<0.005), however neither was there a correlation verified between the variable region length and neutralization potency, nor between PNLG and HIV-1 subtypes. The enrichment of W at top of V3 loop in weak neutralizing response viruses and the P in viruses with higher neutralization susceptibility was statistically significant (p = 0.013). Some other signatures sites were associated to HIV-1 subtype-specific F1 and B/Bbr samples might influence in the distinct neutralizing response. These results indicate that a single amino acid substitution may lead to a distinct conformational exposure or load in the association domain of the trimer of gp120 and interfere with the induction power of the neutralizing response, which affects the sensitivity of the neutralizing antibody and has significant implications for vaccine design.
authors.affiliation: Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute - FIOCRUZ, Rio de Janeiro, Brazil.
authors.forename: Dalziza Victalina
authors.initials: DV
authors.lastname: de Almeida
authors.affiliation: Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute - FIOCRUZ, Rio de Janeiro, Brazil.
authors.forename: Karine Venegas
authors.initials: KV
authors.lastname: Macieira
authors.affiliation: National Institute of Infectology/ FIOCRUZ, Rio de Janeiro, Brazil.
authors.forename: Beatriz Gilda Jegerhorn
authors.initials: BG
authors.lastname: Grinsztejn
authors.affiliation: National Institute of Infectology/ FIOCRUZ, Rio de Janeiro, Brazil.
authors.forename: Valdiléa Gonçalves
authors.initials: VG
authors.lastname: Veloso Dos Santos
authors.affiliation: Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Institute - FIOCRUZ, Rio de Janeiro, Brazil.
authors.forename: Monick Lindenmeyer
authors.initials: ML
authors.lastname: Guimarães
mesh_terms: D057134:Antibodies, Neutralizing / Q000276:immunology*; D001938:Brazil / Q000453:epidemiology; D015483:HIV Antibodies / Q000276:immunology*; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D010802:Phylogeny; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics* / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D054299:env Gene Products, Human Immunodeficiency Virus